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Abstract: Are there common pathways underlying the broad spectrum of tissue pathologies 
that develop upon injuries and from subsequent tissue remodeling? Here, we explain the 
pathophysiological impact of a set of evolutionary conserved danger control programs for 
tissue pathology. These programs date back to the survival benefits of the first multicellular 
organisms upon traumatic injuries by launching a series of danger control responses, i.e.,  
1. Haemostasis, or clotting to control bleeding; 2. Host defense, to control pathogen entry 
and spreading; 3. Re-epithelialisation, to recover barrier functions; and 4. Mesenchymal, to 
repair to regain tissue stability. Taking kidney pathology as an example, we discuss how 
clotting, inflammation, epithelial healing, and fibrosis/sclerosis determine the spectrum of 
kidney pathology, especially when they are insufficiently activated or present in an 
overshooting and deregulated manner. Understanding the evolutionary benefits of these 
response programs may refine the search for novel therapeutic targets to limit organ 
dysfunction in acute injuries and in progressive chronic tissue remodeling. 
Keywords: regeneration; fibrosis; coagulation; stem cells; inflammation; acute kidney 
injury; chronic kidney disease; healing; repair 
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1. Introduction  
Most acute and chronic disorders involve a combination of direct and indirect tissue injuries, i.e., 
the damage caused by the injurious trigger, and that caused by a series of different danger response 
programs, i.e., clotting, inflammation, epithelial regeneration, and mesenchymal repair. These 
processes predominate in a serial manner during acute disorders, with some overlap. However, in 
chronic non-communicable diseases this overlap turns into a concomitant persistence of some of these 
programs, e.g., inflammation and healing, which often leads to significant parenchymal atrophy and 
fibrosis. In this review we use kidney pathology as an example for the spectrum of pathological 
manifestations that derive from these danger response programs and explain why evolution’s  
risk-benefit assessment conserved them across species over time. Better understanding of the origin of 
tissue pathologies should be instrumental to better define target pathways for therapeutic interventions.  
2. Injuries Trigger a Series of Host Response Programs 
Wounding requires immediate actions to control the dangers that come with the injury followed 
either by regeneration or repair, a concept that applies to plants and animals [1,2]. Focal wounding 
requires local danger control, e.g., of pathogen entry, to prevent systemic consequences such as fatal 
sepsis. Hence, such survival benefits from local danger control, outweighs any risk of focal collateral 
injury or tissue remodeling that comes with these danger responses. What remains problematic  
are systemic triggers of danger responses, such as toxic (drugs), hemodynamic (shock or arterial 
hypertension), or metabolic alterations (diabetes, hyperlipidemia) because these induce responses that 
affect multiple organ systems and organ compartments, which implies that any collateral damage 
threatens entire organs, if not the whole body. In the following paragraphs we will introduce the four 
major danger response programs along wound healing after acute skin injury [3–5].  
2.1. Clotting Addresses the Risk of Potentially Fatal Bleeding  
Skin injury causes bleeding, which implies the risk of dying from hemorrhagic shock. Clotting 
addresses this type of danger within minutes by haemolymph aggregation in arthropods, and by a more 
sophisticated interplay of injured endothelial cells, coagulation factors, and platelets in vertebrates [6–9]. 
Overshooting clotting causes tissue ischemia via intravascular coagulation or thromboembolism.  
2.2. Inflammation Addresses the Risk of Fatal Sepsis  
The balance between microbe virulence and host defense has gained considerable complexity along 
the evolution of monocellular organisms [10–13]. Outer surface wounding allows pathogen entry  
and may lead to fatal sepsis, if not immediately addressed by local inflammation to control pathogen 
spreading [14,15]. Extrinsic pathogen-associated molecular patterns (PAMPs) and intrinsic  
damage-associated molecular patterns (DAMPs) act as alarmins that activate the same innate immunity 
pattern recognition receptors in infectious or sterile inflammations [16–21]. Inflammation is already 
activated by clotting, a process referred to as immunothrombosis [6,22–24], as platelet aggregates 
release chemokines that trigger the recruitment of neutrophils [6,25,26]. Overshooting local 
inflammation causes unnecessary immunopathology and loss of parenchyma, e.g., in pyoderma 
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gangraenosum [27,28]. Overshooting systemic inflammation contributes to the early phase of sepsis, 
while insufficient systemic inflammation accounts for lethality in the late phase of sepsis [14,29].  
2.3. Epithelial Regeneration Restores Barrier Functions 
Non-sterile barrier defects require rapid regeneration of the barrier to limit pathogen entry [5,30]. 
Epithelial barriers have also other important functions, such as nutrient absorbtion (gut), gas transfer 
(lungs), or solute secretion/re-absorption (kidney), which require rapid restoration upon injury, e.g., by 
signals that trigger re-epitheliasation from wound borders [2,5,31]. Components of the coagulation 
cascade are the first mediators inside a wound that elicit mitogenic effects on the surviving epithelial 
cells [2,7,25,31,32]. Inflammatory mediators with mitogenic properties, such as epithelial growth 
factors, hepatocyte growth factor, IL-6, IL-17, fractalkine, CXCL10, and IL-22, as well as certain 
miRNAs, stimulate epithelial repair [31,33–40]. Local progenitor cells that are committed to the 
specific epithelial lineage phenotype contribute to re-epithelialisation [30,40–42]. Insufficient  
re-epitheliasation creates chronic wounds, which implies a risk of infections, while overshooting or 
uncoordinated re-epitheliasation, can also cause, problematically, hyperplastic lesions [2,43].  
2.4. Mesenchymal Repair Restores Tissue Stability  
Insufficient re-epithelialisation, loss of tissue parenchyma, or injury to mesenchymal tissues 
activates the wound healing program of mesenchymal repair. This process is needed to stabilize the 
organ’s shape and structure. Insufficient epithelial repair directly stimulates mesenchymal healing, as 
epithelial-mesenchymal transition (EMT) of epithelial cells, and their arrest in the G2/M phase of the 
cell cycle induce the secretion of the pro-fibrotic cytokine TGF-β [44]. The associated accumulation of 
collagen-producing cells [45,46] relates to an influx of bone marrow-derived fibrocytes [47,48], a 
mesenchymal transition of also pericytes and endothelial cells [48,49], as well as the proliferation of 
resident fibroblasts that transform to myofibroblasts [49]. The accumulation of extracellular matrix 
(referred to as fibrosis) stiffens the tissue (referred to as sclerosis). Insufficient mesenchymal healing 
destabilizes tissues while overshooting mesenchymal healing produces fibrotic lesions such as keloid, 
and diffuse fibrotic disorders such as scleroderma. 
In the following we discuss how these ancient danger control programs account for the spectrum of 
organ abnormalities known from pathology textbooks. Based on our own experience we focus to 
kidney pathology. We describe in more detail how common histomorphological abnormalities and 
disease entities develop, either from insufficient, or overshooting danger control programs (Figure 1). 
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Figure 1. Insufficient and predominant danger response programs determine kidney 
pathology. Distinct entities of clinical syndromes or kidney injury patterns are consequences 
of insufficient or overshooting danger control programs. 
 
3. Clotting 
3.1. Overshooting Clotting in the Kidney 
Thrombotic microangiopathies that affect the kidney result from an abnormal activation of 
microvessel endothelial cells, and subsequent activation of platelets and plasmatic coagulation  
(Figure 2) [50,51]. Microvascular clotting causes tissue ischemia and necrosis. In crescentic 
glomerulonephritis, vascular necrosis leads to perforations, ruptures in the glomerular basement 
membrane (GBM), plasma leakage, and bleeding [52]. Glomerular bleeding manifests clinically as 
hematuria, a process that should activate clotting inside the glomerulus. In fact, fibrin deposition is 
usually seen in areas of loop necrosis in crescentic glomerulonephritis, in turn, used as a diagnostic 
marker to identify necrotizing glomerulonephritis [53,54]. In Alport nephropathy, a genetic GBM 
abnormality not associated with intense inflammation, progressive intrinsic degradation and 
disintegration of the GBM, generates similar GBM perforations and ruptures that are associated with 
hematuria, fibrin deposits, and plasma leakage [43]. As part of the clot formation, activated platelets 
release pro-inflammatory and mitogenic factors, which activate subsequent inflammation as well as 
and epithelial regeneration [7,25,26,31,55]. The link of clotting and inflammation, referred to as 
immmunothrombosis, is well defined in the field of immunology and currently understood as a 
mechanism to limit pathogen spreading from the entry site [6,56–59]. This evolutionary conserved 
process certainly contributes to atherosclerosis and -thrombosis, and it is reasonable to assume that this 
link is as important in other non-communicable disorders. 
3.2. Insufficient Clotting in the Kidney  
IgA nephropathy, and several other renal disorders, may present with intermittent macrohematuric 
episodes, implicating that vascular sealing by clotting is insufficient [60]. Urokinase expression further 
down the urinary tract elicits fibrinolytic activity that may maintain the bleeding [61].  
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Figure 2. Overshooting clotting in thrombotic microangiopathy. Local activation 
microvascular endothelial cells and lack of distinct inhibitory factors can lead to 
thrombotic microangiopathy which is characterized by microthrombi obstructing arteriolar 
and glomerular vessels, a lesion associated with significant inflammatory cell infiltrates 
(left). Fibrin immunostaining displayes clot formation within glomeruli (right). Original 
magnification 200×.  
 
4. Inflammation 
4.1. Overshooting Inflammation in the Kidney 
Resident and infiltrating mononuclear phagocytes express the entire spectrum of innate pattern 
recognition receptors that translate danger recognition into a rapid inflammatory response [62,63]. In 
contrast, renal parenchymal cells, i.e., mesangial cells, endothelial cells, podocytes, tubular cells, and 
fibroblasts express only a limited spectrum of such receptors [64,65]. For example, they lack some of 
the endosomal nucleic acid-specific Toll-like receptors, and do not produce IL-1beta upon activation 
of the NLRP3 inflammasome, even though they easily get activated by bacterial endotoxin or  
other PAMPs and DAMPs [66,67]. This mechanism can explain how systemic or extrarenal infections 
can cause flares of pre-existing and smoldering forms of renal inflammation, e.g., chronic 
glomerulonephritis or renal vasculitis. We had addressed this concept by transiently injecting agonists 
to several pattern recognition receptors in mice with experimental immune complex glomerulonephritis, 
which then triggered the intrarenal production of cytokines, type I interferons, which increases 
inflammation and tissue damage [65,68–77]. PAMP-mediated renal inflammation induces the loss of 
renal parenchymal cells, especially podocytes [78,79], because these cannot be easily regenerated [80]. 
For example, mice with Alport nephropathy transiently exposed to bacterial CpG-DNA, display a 
transient activation of resident dendritic cells and infiltrating Ly6Chigh+ macrophages that produce 
pro-inflammatory mediators such as TNF, which triggered podocyte loss and thereby accelerated 
proteinuria and glomerular scarring [78].  
In lupus nephritis, endogenous nucleic acids drive immunity in a similar manner [81,82]. Nuclear 
particles that contain immunostimulatory endogenous RNA and/or DNA activate antigen-presenting 
dendritic cells, macrophages, and B cells, to mature and to release numerous pro-inflammatory 
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mediators including type I interferon [82–84]. The latter sets off a coordinated antiviral immune 
response explaining the similarities between the clinical manifestations of viral infections and systemic 
lupus [85]. This process also occurs inside the kidney, as documented by the antiviral gene expression 
signature in renal biopsies [86,87]. For example, mesangial cells and glomerular endothelial cells use 
their cytosolic nucleic acid sensors to translate nucleic acid recognition into the release of type I 
interferons, which contribute to renal inflammation and tissue damage [88–93].  
Tissue necrosis is associated with a release of endogenous ligands to pattern recognition  
receptors [64,94,95]. For example, postischemic tubular cell necrosis releases HMGB1 and histones 
that ligate TLR2 and TLR4, which trigger an acute intrarenal inflammatory response that determines 
the extent of AKI [66,95–99]. In addition, Tamm-Horsfall protein/uromodulin, a kidney-specific 
protein exclusively expressed within the distal tubule, acts as a TLR4 and NLRP3 agonists when tubular 
injury allows its leakage into the renal interstitium [100,101]. TLR signaling occurs in renal parenchymal 
cells [64] and is tightly regulated in the intrarenal network of dendritic cells by the constitutive and 
induced expression of several inhibitory molecules that are absent or dysfunctional in tubular epithelial 
cells [102–108]. In contrast, the NLRP3 inflammasome enhances tubulointerstitial but not to glomerular 
inflammation [19,109–111], because activated glomerular cells do not induce pro-IL-1β [110].  
Figure 3. Interstitial nephritis in polyoma (BK) virus nephropathy. Local activation of 
inflammation can destroy renal parenchyma and cause acute kidney injury. In this example 
of BK virus reactivation in a kidney allograft was proven by immunostaining for BK viral 
protein with positivity in affected tubular epithelial cells (right). Viral replication activates 
antiviral immunity and immunopathology as evidenced by the dense leukocyte infiltrates in 
the renal interstitium (left). Original magnification 200×.  
 
Triggered by the local release of chemokines, various subsets of leukocytes sequentially recruit into 
the kidney [112–120]. Macrophages, T cells, and B cells polarize into functionally distinct subsets that 
differently affect renal pathology [62,114,121–125]. PAMPs and DAMPs turn non-activated intrarenal 
and circulating mononuclear phagocytes into cells that promote immunopathology [126–128]. 
Blocking the CC-chemokine CCL2, or its receptor CCR2, prevents the recruitment and expansion of 
such classically-activated macrophages, and thereby reduces renal immunopathology in glomeruli and 
the tubulointerstitium, but it does not affect alternatively-activated macrophages [129–137]. Together, 
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the kidney is mostly affected by renal inflammation that is triggered by extrarenal infections that 
release immunostimulatory PAMPs into the circulation, or by intrarenal release of DAMPs that 
promote a sterile inflammatory response [138,139]. These immunostimulatory molecules promote 
unnecessary (collateral) damage to renal cells (Figure 3). 
Thus, suppressing renal inflammation appears as an important strategy to preserve renal tissue, 
especially those epithelial cells that cannot be easily regenerated. Anti-inflammatory drugs that do not 
elicit systemic immunosuppressive effects hold new promise for that [140].  
4.2. Insufficient Inflammation in the Kidney  
While TLR-mediated renal inflammation contributes to inappropriate renal immunopathology in 
sterile nephropathies, it remains an important element of pathogen control in renal infections [66,141]. 
For example, some degree of innate immune activation is needed to keep BK virus in check to avoid 
viral replication and BK virus infection of the allograft [142,143]. The enigmatic importance of  
renal inflammation as part of the local host defense becomes evident also during bacterial 
pyelonephritis [144]. Intrarenal host defense is needed to limit pathogen growth and spreading to 
systemic infections, which happens in TLR4-mutant mice inoculated with uropathogenic E. coli. 
While these mice are protected from renal abscess formation [145], this occurs at the price of 
insufficient pathogen control at the entry site and could cause fatal gram negative sepsis [14]. In 
addition, TLR2 is required for the recognition of leptospiral outer membrane proteins in proximal 
tubular epithelial cells [146]. 
5. Epithelial Regeneration 
Epithelial cells determine most of the kidney’s functions, in the glomerular compartment (filtration 
barrier) as well as the tubular compartment of the kidney (reabsorbtion and secretion). Transient and 
short-term injuries to the tubules are usually followed by sufficient epithelial regeneration that rapidly 
restores renal function [147,148]. Numerous growth factors such as HGF, PDFG, EGF, and BMP-7 
drive the repair of the epithelial monolayers after injury [7,25,31,149]. In addition, the cell cycle 
regulator murine double minute (MDM)-2 assures cell cycle entry of surviving tubular cells by 
inhibiting p53-dependent cell cycle arrest [150], in addition to its role in NF-κB signaling [150,151] 
Epithelial regeneration becomes effective only after the resolution of inflammation [2,5,152]. 
Switching the phenotype of macrophages from a pro-inflammatory (M1) toward an anti-inflammatory 
(M2) is important in this process [122,125,153–156]. This process is associated with the release of 
additional growth factors that drive epithelial recovery in the kidney, including CSF-1 that enhances 
M2 macrophage accumulation [137,152,155–159]. However, epithelial regeneration needs to be tightly 
balanced to avoid renal pathology [80].  
5.1. Overshooting Epithelial Regeneration in the Kidney 
When epithelial (progenitor) cells get heavily activated in the absence of the necessary signals  
for differentiation, overshooting and maladaptive epithelial repair results in additional renal  
pathology [80,160,161]. In rapid progressive glomerulonephritis glomerular vascular necrosis, and 
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subsequent activation of the coagulation cascade, drive intense intraglomerular inflammation [162–164]. 
Both, epithelial injury and inflammation induce the proliferation of parietal epithelial cells without 
their differentiation into podocytes, which would be required for podocyte regeneration [43,161–163]. 
The resulting parietal epithelial cell hyperplasia generates the initial step in glomerular crescent 
formation and nephron loss (Figure 4). This overshooting epithelial hyperplasia does not necessarily 
require inflammation as a trigger. In Col4A3-deficient mice disruption of glomerular capillaries was 
sufficient to trigger parietal epithelial cell hyperplasia [43]. Plasma leakage seemed to be the mitogenic 
stimulus for these epithelial cells that normally reside, devoid of serum contact, in the urinary  
space [165,166].  
Figure 4. Overshooting epithelial regeneration in crescentic glomerulonephritis. Massive 
and uncoordinated proliferation of parietal epithelial cells leads to crescent formation in 
Bowman’s space, e.g., in necrotizing renal vasculitis. Original magnification 100×.  
 
Epithelial hyperplasia in the tubular compartment is less obvious. The tubular progenitor cells are 
located at the junction of glomeruli and proximal tubules, while single progenitor cells are scattered in 
the proximal and distal tubules of the cortex [167,168]. Chevalier et al., have recently demonstrated 
that the phenomenon of atubular glomeruli originates from an obstruction of the tubular lumen by 
epithelial cells [169,170], a process that contributes to tip lesions in focal-segmental glomerulosclerosis 
and diabetic nephropathy [171,172]. 
5.2. Insufficient Epithelial Regeneration in the Kidney 
Insufficient glomerular epithelial (podocyte) regeneration is the predominant cause for chronic 
kidney disease (CKD) and for progression to end stage renal disease (ESRD) (Figure 5). The particular 
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interaction of differentiated podocytes with each other, and with the GBM that maintains the 
glomerular filtration barrier remains a major obstacle for rapid repair [173–176]. This is because 
podocytes involve all their cytoskeleton to maintain the secondary foot processes and the slit 
diaphragm, which is not compatible with reorganizing the cytoskeleton to form the mitotic spindle 
during mitosis [177]. Thus, when podocytes enter the S phase of the cell cycle to undergo hypertrophy, 
cell cycle arrest at the G1 and G2/M restriction points are needed to prevent the podocyte to undergo 
mitosis or, otherwise, podocytes will subsequently detach and die, i.e., mitotic catastrophe [177–180]. 
There has been a controversial debate whether bone marrow-derived progenitors are able to replace 
lost podocytes [181–183], but meanwhile it has been demonstrated that podocytes originate from local 
epithelial progenitors at the urinary pole of the glomerulus that can migrate to the vascular pole and 
differentiate into terminally differentiated podocytes on the glomerular tuft [178,184,185]. This 
process contributes to renal development and podocyte expansion during kidney growth in early 
childhood [101] but its capacity to replace injured podocytes seems to be limited in adults [184,186]. 
The signaling pathways that regulate podocyte renewal from parietal epithelial cells remain to be 
clarified. Notch and Wnt signaling, EGF and SDF-1/CXCL12 seem to have a role [164,178,187,188]. 
Specific epigenetic imprinting at histone H3K9, H3K23 (acetylation), H3K4 (dimethylation), and 
H3K4 phosphorylation at serine 10, which alters gene expression and cell growth, are associated with 
incomplete podocyte recovery [189,190]. 
The persistence of classically-activated mononuclear phagocytes or repetitive/persistent triggers of 
kidney injury also impair epithelial repair in the tubulointerstitial compartment. CSF-1 is a mediator of 
this process [159]. In addition, severe kidney injury may eradicate the tubular progenitor cells that 
have a higher capacity to survive stress [191]. Bone marrow stem cells do not directly replace tubular 
cells by differentiation, but provide paracrine support to the regeneratory capacity of local progenitor 
cells and other surviving epithelial cells [154,168,192–194]. An insufficient regeneration of injured 
tubular epithelial cells will lead to tubular atrophy and nephron loss, a typical characteristic of 
progressive CKD (Figure 5). 
Together, a coordinated epithelial regeneration is needed upon injury, which first requires vascular 
sealing and the resolution of inflammation. Insufficient epithelial regeneration leads to atrophy and 
mesenchymal repair, i.e., tubular atrophy and glomerulosclerosis. Overshooting epithelial repair, i.e., 
hyperplasia, is another form of renal pathology, e.g., the glomerular crescent. Finding ways to enhance 
a coordinated proliferation and differentiation of surviving epithelial cells remains a challenge  
for the future. 
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Figure 5. Insufficient epithelial repair results in mesenchymal repair. Loss of glomerular 
epithelial cells (podocytes) cannot be easily repaired in adults leading to focal-segmental 
glomerulosclerosis (upper left). Global glomerulosclerosis (upper right) results from the 
progression of focal-segmental lesions or as a consequence of diffuse and persistent disease 
mechanisms such as diabetes, hypertension, or immune complex glomerulonephritis. Here 
also, mesangial cells contribute to the sclerosis by excess production of mesangial matrix. 
In chronic kidney disease insufficient tubular regeneration results in tubular atrophy, which 
is usually associated concomitant tubulointerstitial fibrosis. These complex lesions make it 
difficult to appreciate the individual contributing danger response programs. Magnification 
100×–400×.  
 
6. Mesenchymal Repair 
Tissue healing is not limited to epithelia but also includes recovery of vasculature, tendons, fasciae, 
bones, and muscles, all being mesenchymal structures that contribute to function, not only of the 
musculoskeletal system but also to that of solid organs. For example, mesenchymal repair contributes 
to mechanical stabilization of organs like the lung, the heart, and the kidney, which is why epithelial 
growth factors are secreted together with growth factors that stimulate mesenchymal repair, e.g., by 
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increasing the secretion of extracellular matrix components [31]. In skin wounds, dermal fibroblasts 
get activated to transform into myofibroblasts that produce large amounts of type I collagen, which 
promotes wound contraction as a way to reduce wound size for more rapid re-epithelisation [2]. 
Irreversible tissue losses such as in ruptured ligaments or burned skin get filled by fibrous tissue to 
regain tissue stability [2]. These benefits of mesenchymal repair explain why this response program 
was positively selected and maintained along evolution. Solid organs like the kidney, however, often 
suffer from global scarring and progressive fibrosis because of the diffuse nature of the metabolic, 
hemodynamic, and toxic injuries that commonly affect the kidney (Figure 5). [49]. That is why it is not 
at all clear whether diffuse renal fibrosis is an overshooting, or simply a diffuse response. For example, 
interstitial fibrosis in focal-segmental glomerulosclerosis (FSGS) starts in a focal manner around those 
single nephrons that succumb to scarring [173]. The diffuse appearance of interstitial fibrosis only 
develops once many nephrons undergo the same process. The mesenchymal “repair” of each dying 
nephron then leads to confluent fibrotic lesions that give the impression that it is the fibrosis that 
accounts for renal dysfunction [46,49,173,195]. The extracellular matrix mainly replaces lost renal 
epithelia. As such, reducing interstitial fibrosis may result in even smaller kidneys, if not being 
accompanied by sufficient generation of new nephrons, a process which fish can do, but mammals 
cannot [196]. For the sake of didactic clarity, we will continue to use the term “overshooting” 
mesenchymal repair for the discussion of fibrosis as a danger response program that accounts for  
renal pathology. 
6.1. Insufficient Mesenchymal Repair in the Kidney  
Insufficient mesangial repair is a hardly known phenomenon in kidney pathology, or at least  
poorly defined. Mesangiolysis can be considered as a lesion of incomplete mesenchymal repair, but 
mesangiolysis is rarely described in renal biopsies, as it is mostly a transient phenomenon followed by 
rapid, (and often overshooting) mesangial cell recovery [197,198]. Mesangiolysis often results from 
massive renal complement activation, as in C3 glomerulopathies, atypical hemolytic uremic syndrome, 
or immune complex glomerulonephritis [199].  
6.2. Overshooting Mesenchymal Repair in the Kidney 
Mesangial repair after inflammatory injury can occur from three sources: surviving mesangial  
cells [198], from the extraglomerular mesangium [200], and from the bone marrow [201]. Mesangial 
injury rarely occurs in an isolated manner, but complicates diseases that are associated with extensive 
complement activation such as hemolytic uremic syndrome. The rat anti-Thy1.1 model is frequently 
used to study the mechanisms of mesangial repair upon mesangiolysis. Hugo et al., first reported that 
the hyperproliferative response upon mesangiolysis originates from surviving mesangial cells or local 
progenitor cells that reside in the extraglomerular mesangium [200]. Mesangial hyperproliferation also 
contributes to a histopathological lesion named “membrano-proliferative glomerulonephritis” where 
hereditary, or acquired forms, of extensive complement activation within the mesangium lead to a 
persistent expansion of mesangial cells that even extend into the space between the GBM and the 
endothelial cells [202]. The mesangial matrix produced along these mesangial cell extensions stains 
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positive with silver, which then gives glomerular capillaries a splitted GBM appearance on light 
microscopy [202]. 
In the glomerulus this causal relationship becomes clear, as podocyte renewal from local 
progenitors is mostly insufficient, especially in proteinuric disorders of the adult [80,203]. In FSGS, 
parietal epithelial cells rather produce extracellular matrix, and generate segmental sclerotic lesions, 
than regenerating lost podocytes [204]. This focal synechia has still the potential to stabilize the  
focal loss of podocytes as in some forms of secondary FSGS [171]. However, beyond a certain amount 
of lost podocytes, the scarring process acquires its own dynamic and progresses to global 
glomerulosclerosis [175], because hyperfiltration of the remaining glomerulus adds more hemodynamic 
stress on the surviving podocytes [173,205]. The mesenchymal transition of parietal epithelial cells 
further contributes to fibrocellular crescent formation, implying an irreversible loss of the entire 
nephron [206]. In this way, parietal epithelial cells directly contribute, not only to epithelial, but also to 
mesenchymal repair [166]. 
The process of epithelial-mesenchymal transition of surviving epithelial cells that cannot  
rapidly regenerate epithelial injuries has attracted a lot of attention [46,207–209]. It is based on the 
observation that epithelial cells of mesenchymal origin, like the renal epithelia, re-express 
mesenchymal markers upon injury in vitro and in vivo [46]. This has led to the assumption that such 
cells could leave tubular compartment and migrate into the renal interstitium where they may fuel into 
the heterogeneous pool of fibroblasts and contribute extracellular matrix production and fibrotic 
lesions [46,49]. The significance of this phenomenon for human kidney disease remains under  
debate because clear evidence for tubular cells leaving the tubular compartment in vivo is still  
lacking [46,207–209]. In the glomerulus, however, parietal epithelial cells that do not adequately 
differentiate into podocytes clearly undergo this mesenchymal transition and cause scarring, as there is 
no need for them to leave their home compartment (Figure 5) [43,206].  
The concept that renal interstitial fibrosis accounts for renal dysfunction originates from the close 
association of the extent of renal fibrosis with poor outcomes of primary glomerular disorders [210], 
but functional studies do not always support this causal relationship [49,196]. It is of note that the 
driving factor of interstitial fibrosis seems to be epithelial injury and insufficient epithelial  
repair [211], e.g., when proliferating epithelial cells get arrested in the G2/M phase and start to 
produce tumor growth factor-beta [44]. This process is also triggered by aristocholic acid [44,212], the 
nephrotoxic element of Chinese herb nephropathy [213]. Bone marrow progenitor cells and leukocytes 
enhance the process of renal fibrosis, as evidenced by experimental interventions that block leukocyte 
recruitment and can prevent interstitial fibrosis either as a direct or an indirect effect [112,134,214–219]. 
For example, inhibition, genetic deletion, or depletion of alternatively-activated (M2) macrophages 
protects from renal fibrosis [122,155,156,220–227]. Fibrocytes are a particular type of Ly6G+ 
collagen-producing cell that originate from myeloid precursors in the bone marrow and that recruit to 
sites of chronic kidney injury [228,229]. Ly6G+ fibrocytes specifically recruit via CCL21-CCR7 and 
not via CCL2-CCR2 like pro-inflammatory macrophages, but once they reach the kidney they 
contribute to local collagen deposition and interstitial fibrosis [230,231]. 
Vascular reconstruction is another element of mesenchymal healing [232]. Pericytes stabilize 
microvessels not only during homeostasis, but also during microvessel recovery, a process mediated 
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by TIMP3 and ADAMTS1 [233]. Their capacity to produce collagen adds pericytes to the list of cells 
that contribute to renal interstitial fibrosis and sclerosis [234]. 
Together, mesenchymal repair is needed to stabilize and rebuild tissues after injury, especially after 
loss of parenchymal tissue. Insufficient scarring is rarely a problem in the kidney. In contrast, scarring 
within the glomerulus, usually upon dysregulated epithelial repair like in podocyte loss, or crescent 
formation, is the greatest concern as FSGS and fibrocellular crescents both eventually lead to loss of 
the entire nephron (Figure 5). Within the interstitial compartment fibroblast- and pericyte-derived 
extracellular matrix fills the gaps left by dying nephrons and, this way, stabilizes the remaining 
nephrons. This process, however, further contributes to vascular rarefication and renal ischemia and is 
thought to further promote the progression of kidney disease. Hence, an otherwise beneficial wound 
healing response turns into a maladaptive process that promotes organ failure, mainly because of the 
diffuse nature of most kidney diseases. 
7. Summary 
Clotting, inflammation, epithelial, and mesenchymal healing represent ancient danger response 
mechanisms that were positively selected throughout evolution for their benefits on host survival upon 
focal injury. In focal injuries the associated collateral damages may be acceptable. In contrast, in 
diffuse injuries, as they usually affect the kidney, these danger response programs often turn into 
maladaptive pathomechanisms that account for organ failure. Research efforts can benefit from 
dissecting these individual danger response programs, and from studying their regulatory interactions. 
From a therapeutic perspective, inhibiting the unnecessary inflammatory response in renal sterile 
inflammation and stimulating a coordinated epithelial repair should be the most promising strategies to 
avoid kidney pathology and disease progression. 
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